Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose
A 59-year-old woman had recurrences in the spleen and lung 10 years after radical excision of cecal cancer. After 27 months of treatment with 5-fluorouracil/Leucovorin, oxaliplatin, irinotecan, bevacizumab, and anti-EGFR antibodies, multiple bone metastases and a left adrenal metastasis developed, and the patient's performance status (PS) deteriorated to grade 3. Regorafenib was administered at 80 mg/day. The pain and appetite improved within 2 courses, and her PS improved from grade 3 to 2. Regorafenib was increased to 120 mg/day for the 2nd course, and the patient was treated for 5 months without severe adverse effects. Regorafenib is considered to be a salvage-line treatment only for patients in relatively good condition, because full-dose regorafenib treatment often leads to severe adverse effects. Dose escalation of regorafenib from the low initial dose of 80 mg/day may be a safe and effective way of providing an opportunity of this chemotherapy to patients with impaired PS.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Gan to kagaku ryoho. Cancer & chemotherapy - 42(2015), 7 vom: 22. Juli, Seite 871-3 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Nishitai, Ryuta [VerfasserIn] |
|---|
| Themen: |
24T2A1DOYB |
|---|
| Anmerkungen: |
Date Completed 10.09.2015 Date Revised 22.07.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM251106039 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM251106039 | ||
| 003 | DE-627 | ||
| 005 | 20231224161300.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||jpn c | ||
| 028 | 5 | 2 | |a pubmed24n0837.xml |
| 035 | |a (DE-627)NLM251106039 | ||
| 035 | |a (NLM)26197753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Nishitai, Ryuta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 10.09.2015 | ||
| 500 | |a Date Revised 22.07.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 59-year-old woman had recurrences in the spleen and lung 10 years after radical excision of cecal cancer. After 27 months of treatment with 5-fluorouracil/Leucovorin, oxaliplatin, irinotecan, bevacizumab, and anti-EGFR antibodies, multiple bone metastases and a left adrenal metastasis developed, and the patient's performance status (PS) deteriorated to grade 3. Regorafenib was administered at 80 mg/day. The pain and appetite improved within 2 courses, and her PS improved from grade 3 to 2. Regorafenib was increased to 120 mg/day for the 2nd course, and the patient was treated for 5 months without severe adverse effects. Regorafenib is considered to be a salvage-line treatment only for patients in relatively good condition, because full-dose regorafenib treatment often leads to severe adverse effects. Dose escalation of regorafenib from the low initial dose of 80 mg/day may be a safe and effective way of providing an opportunity of this chemotherapy to patients with impaired PS | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Phenylurea Compounds |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a regorafenib |2 NLM | |
| 650 | 7 | |a 24T2A1DOYB |2 NLM | |
| 700 | 1 | |a Manaka, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Kudo, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Mitsuoka, Eisei |e verfasserin |4 aut | |
| 700 | 1 | |a Kanai, Shumpei |e verfasserin |4 aut | |
| 700 | 1 | |a Kanto, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Hamasu, Shin-ya |e verfasserin |4 aut | |
| 700 | 1 | |a Konishi, Sayuri |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashiro, Yutaka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gan to kagaku ryoho. Cancer & chemotherapy |d 1993 |g 42(2015), 7 vom: 22. Juli, Seite 871-3 |w (DE-627)NLM012601861 |x 0385-0684 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2015 |g number:7 |g day:22 |g month:07 |g pages:871-3 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2015 |e 7 |b 22 |c 07 |h 871-3 | ||